Table 4.
Major adverse cardiac events and stent thrombosis at 30 days and one-year follow-up
| Netherlands | Germany | France | p-value | Total study population | |||||
|---|---|---|---|---|---|---|---|---|---|
| n = 420 | n = 165 | n = 131 | n = 965 | ||||||
| Events at 30 days | Patients | Event rate* (percentage) | Patients | Event rate* (percentage) | Patients | Event rate* (percentage) | – | Patients | Event rate (percentage) |
| MACE | 18 | 4.3 | 5 | 3.1 | 0 | – | 0.053 | 34 | 3.5 |
| Definite/probable ST | 17 | 4.1 | 5 | 3.1 | 0 | – | 0.066 | 30 | 3.1 |
| – Definite ST | 15 | 3.6 | 3 | 1.8 | 0 | – | 0.061 | 24 | 2.5 |
| – Probable ST | 2 | 0.5 | 2 | 1.2 | 0 | – | 0.350 | 6 | 0.6 |
| Events at one-year | Patients | Event rate* (percentage) | Patients | Event rate* (percentage) | Patients | Event rate* (percentage) | – | Patients | Event rate (percentage) |
| MACE | 32 | 7.7 | 21 | 12.7 | 12 | 9.2 | 0.112 | 86 | 8.9 |
| Definite/probable ST | 17 | 4.1 | 6 | 3.6 | 0 | – | 0.070 | 33 | 3.5 |
| – Definite ST | 15 | 3.6 | 4 | 2.4 | 0 | – | 0.085 | 27 | 2.8 |
| – Probable ST | 2 | 0.5 | 2 | 1.2 | 0 | – | 0.350 | 6 | 0.6 |
*Kaplan-Meier estimates. P-value with log rank test
MACE major adverse cardiac events (defined as the composite of cardiac death, recurrent target-vessel related myocardial infarction and clinically-driven target lesion revascularization), ST stent thrombosis